PEDIATRIC NEPHROLOGY, vol.28, no.1, pp.155-158, 2013 (SCI-Expanded)
Article / Article
Science Citation Index Expanded (SCI-EXPANDED), Scopus
Atypical hemolytic uremic syndrome, Complement factor H mutation, Eculizumab, Newborn, MUTATIONS
Hacettepe University Affiliated:
Atypical hemolytic uremic syndrome (aHUS) is characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and renal impairment. Neonatal cases are extremely uncommon. Plasma therapy is the first choice therapy in patients with aHUS based on the belief of an underlying complement dysregulation. Alternatively, eculizumab, which targets complement 5, is used to block complement activation.